Schott Pharma (ETR: 1SXP) Shares Jump 4% as Barclays Upgrades Stock to Overweight on Growth Inflection
Key Points
Barclays upgraded Schott Pharma to Overweight, raising the target to €27.
Shares jumped 6.5%, hitting a new 52-week high of €23.
Growth expected to accelerate from 5.8% to 8.6% by FY2030.
Single GLP-1 customer accounts for roughly 10% of group revenue.
Schott Pharma shares jumped as much as 6.5% on August 18, 2026, hitting a new 52-week high of €23. Barclays upgraded the stock to “overweight” from “equal weight” and raised its price target to €27 from €16. Analyst Jonathon Unwin cited a genuine growth inflection after three years of declining earnings estimates. The upgrade reflects renegotiated contracts and improving demand for injectable drug packaging.
Why Barclays Turned Bullish on Schott Pharma
Renegotiated Contracts Signal a Turning Point
Barclays (NYSE: BCS) analyst Jonathon Unwin pointed to newly renegotiated contracts as the key catalyst behind this upgrade. These deals support Schott’s ready-to-use primary packaging and specialty vial businesses. After three years of downward earnings revisions, Unwin now expects a genuine trend reversal for the pharmaceutical packaging specialist.
High-Value Solutions Drive the Growth Case
Schott Pharma derives roughly 60% of revenue from high-value solutions, the highest exposure among sector peers. This segment includes advanced drug delivery systems tied to rising biologics adoption. Barclays expects this mix to support high-single-digit to low-double-digit revenue growth, translating into stronger operating leverage over time.
Schott Pharma’s Growth Trajectory Through Fiscal 2030
Revenue Growth Set to Accelerate
Barclays forecasts Schott Pharma’s growth accelerating from 5.8% in fiscal 2026 to 8.6% by fiscal 2030. The company now sits 3% ahead of Bloomberg consensus EBITDA estimates for fiscal 2030. It also runs 6% ahead of consensus EPS projections, reinforcing Barclays’ confidence in sustained earnings momentum ahead.
Shares Have Already Outperformed Peers Sharply
Schott Pharma shares are up 45% year-to-date, compared with a 2% decline in the SXDP sector index. That outperformance stems partly from a broader peer group rerating. An upgraded fiscal 2026 guidance from the company itself also helped drive investor confidence throughout the year.
Market Tailwinds Behind Schott Pharma’s Rally
Injectable Drug Demand Keeps Rising
Thirty years of FDA approval data show accelerating use of injectable drugs, especially pre-filled syringes. Biologics and biosimilars continue driving this shift. Barclays sees glass packaging specialists like Schott Pharma as direct beneficiaries of this trend, alongside rising demand tied to GLP-1 weight-loss drug manufacturing.
Primary Packaging Market Set to Expand
Barclays forecasts the global primary packaging market growing at a 7% compound annual rate from 2025 through 2030. That expansion supports Schott Pharma’s core vials, syringes, and cartridge businesses. Competing glass packaging names include Gerresheimer and Stevanato Group, both operating in similar pharmaceutical containment markets.
Risks That Could Slow Schott Pharma’s Momentum
Customer Concentration Remains a Key Risk
A single customer in the GLP-1 space now accounts for roughly 10% of Schott Pharma’s group revenue. Barclays flagged this concentration as the primary risk to its bullish thesis. Any shift in that customer’s ordering patterns could meaningfully affect Schott’s near-term revenue trajectory.
Delivery Format Changes Add Uncertainty
Eli Lilly (NYSE: LLY) received FDA approval in February 2026 to sell Zepbound in a pen-injector rather than an auto-injector. That shift could reduce demand for higher-margin glass pre-filled syringes over time. Schott Pharma has stated it currently sees no change in customer order behavior tied to this approval.
Final Thoughts
Barclays’ upgrade marks a meaningful shift in sentiment after years of earnings downgrades for Schott Pharma. Renegotiated contracts and rising injectable drug demand support the bullish case. Customer concentration risk remains real, but the current trajectory suggests genuine operational improvement rather than a temporary rebound.
Disclaimer:
The content shared by Meyka AI PTY LTD is for research and informational purposes only. Meyka is not a financial advisory service, and the information provided should not be treated as investment or trading advice.
What brings you to Meyka?
Pick what interests you most and we will get you started.
I'm here to read news
Find more articles like this one
I'm here to research stocks
Ask Meyka Analyst about any stock
I'm here to track my Portfolio
Get daily updates and alerts (coming March 2026)